Activity Goals. Activity Goals Discussion Topics.

Slides:

Advertisements

Similar presentations

Moskowitz CH et al. Proc ASH 2014;Abstract 290.

Advertisements

이근욱 분당서울대학교병원/서울의대 혈액종양내과 부교수

Blood-based biomarkers for cancer immunotherapy: Tumor mutational burden in blood (bTMB) is associated with improved atezolizumab (atezo) efficacy in.

Recent Advances in NSCLC Treatment

Statistical Considerations for Safety Assessment in Cancer Immunotherapy Trials Andrew Lloyd Biometrics Manager PSI Conference May 2017.

Advancing Care Forward in Squamous Cell Carcinoma of the Head and Neck

Bladder Cancer: A New Era in Treatment

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

The Nurse View: Management of Pancreatic Cancer

COMPLICATIONS OF IMMUNOTHERAPY IN THE HOSPITALIZED PATIENT Vivek Batra MD, Emma Weaver MD Division of Medical Oncology, Thomas Jefferson University, Philadelphia.

Case Discussion A 52-year-old man initially presented with nonmuscle-invasive bladder cancer He received Bacillus calmette-guerin (BCG) therapy After.

Evolving Paradigms in Recurrent/Metastatic SCCHN

Nat. Rev. Clin. Oncol. doi: /nrclinonc

A New Path Forward: Immune Checkpoint Inhibitors in Bladder Cancer

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data.

The Immune System. The Immune System Adaptive Immune Response.

Program Goals. Clinical Considerations in the Use of Checkpoint Inhibitors for Gastrointestinal Cancers.

Advanced NSCLC Without Actionable Mutations

State of the Art in HCC: Immune Checkpoint Modulation

New Patient Journeys in Non-small cell lung cancer

Discussion Outline Cells of the Immune System.

Essential Concepts in Harnessing the Immune System in Head and Neck Cancer.

Metastatic Renal Cell Carcinoma

Learning Objectives. A Multidisciplinary Approach in Advanced NSCLC in the Era of Immuno-Oncology.

Updates in Lung Cancer: Insights From Vienna

Optimizing the Treatment of Recurrent/Metastatic SCCHN

The Nurse View: Overcoming Challenges Associated With Cancer Immunotherapy.

Determining the Best Treatment Algorithm for Patients With Head and Neck Cancer.

Program Goals Introduction Case 1: A 44-Year-Old Woman.

The Evolving Role of Immunotherapy in NSCLC

Immunotherapy in Pancreatic Cancer: Thinking Outside the Box

Locally Advanced NSCLC Implementing Innovation

Optimizing Management of Advanced Bladder Cancer

Basics of Immunotherapy Potential Therapeutic Targets.

Advanced Lung Cancers: What's on the Horizon?

Clinical Pearls on the Management of Immune-Mediated Adverse Events Affecting the Genitourinary Tract.

The Emerging Role of Immunotherapy in Hodgkin Lymphoma

Presented By Johanna Bendell at 2016 ASCO Annual Meeting

Essential Concepts in the Use of Immunotherapies in Bladder Cancer

Immunotherapy for cSCC

Advancing Care in Genitourinary Cancer: Perspectives From Chicago

Evolving Concepts in the Management of Head and Neck Cancers

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Advances in Gastrointestinal Cancers

Treatment of Locally Advanced Pancreatic Cancer

Changing the Paradigm of Treatment in Patients With Hodgkin Lymphoma

Targeting T Cell Co-receptors for Cancer Therapy

Patient-Centered Management in Advanced Non-Small Cell Lung Cancer

Practical Guidance on the Management of Pan-Negative NSCLC

Challenges in LA SCCHN.

Preparing for Checkpoint Inhibitors in Breast Cancer

Novel Concepts in the Management of RCC

From Adjuvant to Metastatic in Melanoma

Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC

The Nurse View: Spotlight on Immune Checkpoint Inhibitors in Advanced Lung Cancer.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Activity Goals. Clinical Considerations in the Use of Immune Checkpoint Inhibitors in Advanced NSCLC.

Optimizing Outcomes in mRCC: Finding the Balance of Immune Inhibition

This program will include a discussion of off-label treatment or use of investigational agents not approved by the FDA for use in the US, and data that.

Checkpoint Inhibitors in First-Line Advanced NSCLC

Activity Goals. Clinical Considerations in the Use of Checkpoint Inhibitors for Genitourinary Cancers.

Clinical Considerations in the Use of Checkpoint Inhibitors Breast Cancer.

Going Beyond EXTREME in Head and Neck Cancer

Moving Care Forward in Advanced Gastric Cancer

Combining Immunotherapy and Chemotherapy in NSCLC

The Nurse View: Practice Pearls in the Use of Immune Checkpoint Inhibitors in Advanced NSCLC.

Recent Developments in the Treatment of Advanced and Metastatic RCC

Presentation transcript:

Activity Goals

Discussion Topics

Current Treatment Paradigm for Locally Advanced/Metastatic Bladder Cancer

Challenges With Cisplatin-Based Therapy

Discovery of Bacillus Calmette-Guérin (BCG)

T-Cell Biology

The Use of Immunotherapy in Bladder Cancer -- Checkpoint Inhibition Strategies

KEYNOTE-012: Pembrolizumab in Advanced Bladder Cancer

KEYNOTE-012: Results

KEYNOTE-012: Response Duration and Safety

IMvigor 210: Atezolizumab in mUC

IMvigor 210: Patient Population

IMvigor 210: Response Rates

IMvigor 210: Durable Responses

IMvigor 210: Overall Survival

IMvigor 210: Adverse Events

JAVELIN Trial: Avelumab in mUC

JAVELIN Trial: Results

Phase 2: Gemcitabine + Cisplatin + Ipilimumab in mUC

Gemcitabine + Cisplatin + Ipilimumab in mUC: Trial Design

Gemcitabine + Cisplatin + Ipilimumab in mUC: Results

Gemcitabine + Cisplatin + Ipilimumab in mUC: Safety

Biomarkers of Response: Who Benefits From Immunotherapy?

Relationship Between Immune-Related Gene Expression Signatures and Outcomes

Populations of Interest

Selected Enrolling Clinical Trials: Pembrolizumab

Selected Enrolling Clinical Trials: Nivolumab and Ipilimumab

Selected Enrolling Clinical Trials: Atezolizumab

Selected Enrolling Clinical Trials: Avelumab

Abbreviations

Abbreviations (cont)